Condition
Solar Urticaria
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02262130Phase 2CompletedPrimary
Omalizumab in Severe and Refractory Solar Urticaria
NCT01360658Phase 2CompletedPrimary
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
NCT00859534Phase 2CompletedPrimary
Phase II Solar Urticaria (SU) Pilot Study
Showing all 3 trials